We are live on ! Find out more
ELOX

Eloxx Pharmaceuticals, Inc. Common Stock
ELOX

Delisted

ELOX was delisted on the 13th of October, 2023.

Back to rankings

16 hedge funds and large institutions have $924K invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $672K → $924K (+$253K)

16% less funds holding

Funds holding: 19 → 16 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
16
Holders Change
-3
Holders Change %
-15.79%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$4.76K
2
TRCT
Tower Research Capital (TRC)
New York
+$397
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$122
4
Wells Fargo
Wells Fargo
California
+$6

Top Sellers

Rank Fund Capital Flow
1
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$74K
2
UBS Group
UBS Group
Switzerland
-$1.18K
3
Bank of America
Bank of America
North Carolina
-$931
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Silverarc Capital Management
Massachusetts
$210K – – –
MMH
2
Menora Mivtachim Holdings
Israel
$204K – – –
AFG
3
American Financial Group
Ohio
$144K – – –
AS
4
Altshuler Shaham
Israel
$97.7K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$80.5K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$78.8K +$122 +19 +0.1%
CI
7
Clal Insurance
Israel
$57K – – –
BlackRock
8
BlackRock
New York
$34.6K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$9.64K +$397 +62 +3%
Wells Fargo
10
Wells Fargo
California
$4.54K +$6 +1 +0.1%
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$3K +$4.76K +743 +1,728%
Morgan Stanley
12
Morgan Stanley
New York
$307 – – –
MAM
13
Meeder Asset Management
Ohio
$58 – – –
Group One Trading
14
Group One Trading
Illinois
$16 – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$4 – – –
NC
16
NewSquare Capital
Pennsylvania
$4 – – –
HIIFS
17
Harel Insurance Investments & Financial Services
Israel
– -$74K -29,410 Closed
UBS Group
18
UBS Group
Switzerland
– -$1.18K -469 Closed
Bank of America
19
Bank of America
North Carolina
– -$931 -371 Closed

ELOX Hedge Fund Activity: Q2 2023 in Review

16 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q2 2023, worth a combined $924K — up 38% from $672K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ELOX and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 4 added.

The largest buyer was Royal Bank of Canada, adding an estimated $4.76K. The largest seller was Harel Insurance Investments & Financial Services, exiting entirely with an estimated $74K sold.

  • 16 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q2 2023, down from 19 in Q1 2023.
  • Funds reported $924K of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q2 2023, up 38% quarter-over-quarter.
  • 0 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of -3 holders.
  • The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q2 2023 was Royal Bank of Canada, an estimated $4.76K added.
  • The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q2 2023 was Harel Insurance Investments & Financial Services, an estimated $74K sold.

Based on aggregated 13F filings for Q2 2023.